Insider trading

Period: 12 months Stock: NTRA Role: Other officers × Minimum amount: $1M × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

23 decisions over 12 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

23 decisions over 12 months Remove this filter
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

23 decisions over 12 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

23 decisions over 12 months Remove this filter
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
23 decisions over 12 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
23 decisions over 12 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

23 decisions over 12 months
Stock
Insider
Type ?
Why it stands out
1 Oct 2026
Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS
Sold on a plan 3×
$1.24M 3,000 at 414.22
2.7%
Planned (10b5-1)
15 Sep 2026
Rabinowitz Matthew EXECUTIVE CHAIRMAN
Sold on a plan 13×
$17.36M 50,000 at 347.19
2.3%
Planned (10b5-1)
14 Sep 2026
Rabinowitz Matthew EXECUTIVE CHAIRMAN
Sold on a plan 15×
$16.74M 50,000 at 334.76
2.2%
Planned (10b5-1)
11 Sep 2026
Rabinowitz Matthew EXECUTIVE CHAIRMAN
Sold on a plan 6×
$16.40M 50,000 at 327.97
2.2%
Planned (10b5-1)
2 Sep 2026
Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS
Sold on a plan
$4.96M 15,160 at 326.89
12.0%
Planned (10b5-1)
10 Aug 2026
Fesko John PRESIDENT, CHIEF BUS. OFFICER
Sold on a plan
$2.10M 6,517 at 321.53
3.2%
Planned (10b5-1)
1 Jul 2026
RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER
Sold on a plan 12×
$4.57M 16,800 at 272.29
8.9%
Planned (10b5-1)
24 Jun 2026
RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER
Sold on a plan 4×
$8.46M 33,600 at 251.65
15.1%
Planned (10b5-1)
15 Jun 2026
Rabinowitz Matthew EXECUTIVE CHAIRMAN
Sold on a plan 10×
$10.75M 50,000 at 214.91
2.1%
Planned (10b5-1)
12 Jun 2026
Rabinowitz Matthew EXECUTIVE CHAIRMAN
Sold on a plan 11×
$10.70M 50,000 at 214.03
2.1%
Planned (10b5-1)
5 May 2026
Rabinowitz Matthew EXECUTIVE CHAIRMAN
Sold on a plan 4×
$1.49M 6,986 at 213.77
0.3%
Planned (10b5-1)
1 Apr 2026
RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER
Sold on a plan 5×
$1.71M 8,400 at 203.31
3.6%
Planned (10b5-1)
16 Mar 2026
Rabinowitz Matthew EXECUTIVE CHAIRMAN
Sold on a plan 8×
$9.81M 50,000 at 196.28
2.1%
Planned (10b5-1)
13 Mar 2026
Rabinowitz Matthew EXECUTIVE CHAIRMAN
Sold on a plan 5×
$14.18M 75,000 at 189.01
3.1%
Planned (10b5-1)
12 Mar 2026
Rabinowitz Matthew EXECUTIVE CHAIRMAN
Sold on a plan 10×
$14.29M 75,000 at 190.59
3.1%
Planned (10b5-1)
6 Mar 2026
RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER
Sold on a plan 5×
$1.65M 8,398 at 196.08
3.5%
Planned (10b5-1)
20 Jan 2026
Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS
Sold on a plan
$5.45M 23,205 at 234.74
13.8%
Planned (10b5-1)
20 Jan 2026
RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER
Sold on a plan
$4.51M 19,234 at 234.74
7.8%
Planned (10b5-1)
20 Jan 2026
Fesko John PRESIDENT, CHIEF BUS. OFFICER
Sold on a plan
$4.18M 17,806 at 234.74
9.1%
Planned (10b5-1)
12 Dec 2025
Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS
Sold at will
$1.08M 4,692 at 230.76
4.0%
Not planned
4 Nov 2025
Rabinowitz Matthew EXECUTIVE CHAIRMAN
Sold on a plan 2×
$4.59M 22,900 at 200.51
1.0%
Planned (10b5-1)
3 Nov 2025
Rabinowitz Matthew EXECUTIVE CHAIRMAN
Sold on a plan
$3.42M 17,100 at 200.00
0.7%
Planned (10b5-1)
20 Oct 2025
Rabinowitz Matthew EXECUTIVE CHAIRMAN · indirect
Sold on a plan
$1.90M 10,000 at 190.00
66.7%
Sold half or more
Showing 1–23 of 23.